Novus Biologicals Announces New CHD7 Antibody Made Using SDIX Genomic Antibody Technology
Summary
The ability of any antibody to recognize a protein’s naturally folded state has the potential to expand an antibody’s utility to high-value applications like sandwich immunoassay, ChIP and flow cytometry.For over 20 years, SDIX has been a leading immuno-solutions Company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost effective results.These syndromes are characterized by a wide range of symptoms, and are thought to affect neurogenerative anomalies and maturation events through SOX2 interaction.Novus new CHD7 Antibody (NBP1-77393) has been thoroughly validated for use in Western blot and immunofluorescent staining on human and mouse samples.Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIXs public filings with the U.S. Securities and Exchange Commission.### Contact Information Novus Biologicals Amy Chamberlain-Torres 303-730-1950 www.NovusBio.com Click here to view the list of recent Press Releases from Novus Biologicals Promote Your Business Press Release Pricing Email this page to a friend